Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0780 and AZD4954 Pharmacokinetics in Healthy Adults
NCT07513571Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of laropiprant and AZD4954 in hypercholesterolemia (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Area under concentration time curve from time 0 to infinity and Maximum observed drug concentration. Started Apr 2026; status: completed.
02
Drugs
laropiprantAZD4954
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07513571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513571.